174 related articles for article (PubMed ID: 23927854)
1. Optimal policies of non-cross-resistant chemotherapy on Goldie and Coldman's cancer model.
Chen JH; Kuo YH; Luh HP
Math Biosci; 2013 Oct; 245(2):282-98. PubMed ID: 23927854
[TBL] [Abstract][Full Text] [Related]
2. The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics.
Gaffney EA
Bull Math Biol; 2005 May; 67(3):563-611. PubMed ID: 15820743
[TBL] [Abstract][Full Text] [Related]
3. The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling.
Gaffney EA
J Math Biol; 2004 Apr; 48(4):375-422. PubMed ID: 15052504
[TBL] [Abstract][Full Text] [Related]
4. Some drug-resistant models for cancer chemotherapy. Part 1: Cycle-nonspecific drugs.
Usher JR; Henderson D
IMA J Math Appl Med Biol; 1996 Jun; 13(2):99-126. PubMed ID: 8671582
[TBL] [Abstract][Full Text] [Related]
5. Minimizing drug resistance. The somatic mutation model and gestational trophoblastic neoplasia.
Dembo AJ
J Reprod Med; 1987 Sep; 32(9):669-74. PubMed ID: 2822921
[TBL] [Abstract][Full Text] [Related]
6. [Kinetics of breast neoplasms].
Surbone A; Norton L
Minerva Med; 1994; 85(1-2):7-16. PubMed ID: 8152580
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture.
Bonadonna G
Cancer Res; 1982 Nov; 42(11):4309-20. PubMed ID: 6181867
[TBL] [Abstract][Full Text] [Related]
8. [General principles of dose-effect relationship].
Borg C; Trillet-Lenoir V
Bull Cancer; 2001 Sep; 88(9):833-4. PubMed ID: 11604354
[TBL] [Abstract][Full Text] [Related]
9. [Cancer chemotherapy; past, present and future--from the aspect of fundamental studies].
Tukagoshi S
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1398-403. PubMed ID: 14584271
[TBL] [Abstract][Full Text] [Related]
10. Optimal drug regimens in cancer chemotherapy: a multi-objective approach.
Batmani Y; Khaloozadeh H
Comput Biol Med; 2013 Dec; 43(12):2089-95. PubMed ID: 24290925
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous mutation to chemotherapy resistance: implications of the Goldie-Coldman model for the management of ovarian cancer.
Dembo AJ
J Clin Oncol; 1984 Dec; 2(12):1311-6. PubMed ID: 6512579
[No Abstract] [Full Text] [Related]
12. Delay equations modeling the effects of phase-specific drugs and immunotherapy on proliferating tumor cells.
Barbarossa MV; Kuttler C; Zinsl J
Math Biosci Eng; 2012 Apr; 9(2):241-57. PubMed ID: 22901063
[TBL] [Abstract][Full Text] [Related]
13. Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy.
Boldrini JL; Costa MI
IMA J Math Appl Med Biol; 2000 Mar; 17(1):33-51. PubMed ID: 10757031
[TBL] [Abstract][Full Text] [Related]
14. Optimal robust control of drug delivery in cancer chemotherapy: a comparison between three control approaches.
Moradi H; Vossoughi G; Salarieh H
Comput Methods Programs Biomed; 2013 Oct; 112(1):69-83. PubMed ID: 23891423
[TBL] [Abstract][Full Text] [Related]
15. Stochastic modeling of drug resistance in cancer.
Komarova N
J Theor Biol; 2006 Apr; 239(3):351-66. PubMed ID: 16194548
[TBL] [Abstract][Full Text] [Related]
16. What does not kill a tumour may make it stronger: In silico insights into chemotherapeutic drug resistance.
Hamis S; Nithiarasu P; Powathil GG
J Theor Biol; 2018 Oct; 454():253-267. PubMed ID: 29909142
[TBL] [Abstract][Full Text] [Related]
17. On assessing quality of therapy in non-linear distributed mathematical models for brain tumor growth dynamics.
Bratus AS; Fimmel E; Kovalenko SY
Math Biosci; 2014 Feb; 248():88-96. PubMed ID: 24384228
[TBL] [Abstract][Full Text] [Related]
18. Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy.
Cho H; Levy D
Bull Math Biol; 2017 Dec; 79(12):2986-3012. PubMed ID: 29022203
[TBL] [Abstract][Full Text] [Related]
19. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy.
Day RS
Cancer Res; 1986 Aug; 46(8):3876-85. PubMed ID: 3731062
[TBL] [Abstract][Full Text] [Related]
20. Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy.
Ledzewicz U; Schättler H
Math Biosci; 2007 Apr; 206(2):320-42. PubMed ID: 16197967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
